JPMorgan Chase set a GBX 7,000 ($94.95) target price on Reckitt Benckiser (LON:RB) in a report issued on Friday morning. The brokerage currently has a buy rating on the stock.
A number of other equities analysts have also issued reports on RB. UBS set a GBX 7,000 ($94.95) price target on Reckitt Benckiser and gave the stock a neutral rating in a report on Thursday, January 11th. Liberum Capital reissued a buy rating and set a GBX 8,000 ($108.52) price target on shares of Reckitt Benckiser in a report on Monday, January 15th. Citigroup set a GBX 7,900 ($107.16) price target on Reckitt Benckiser and gave the stock a buy rating in a report on Tuesday, January 16th. Berenberg Bank set a GBX 7,900 ($107.16) price target on Reckitt Benckiser and gave the stock a buy rating in a report on Friday, January 19th. Finally, Barclays set a GBX 6,700 ($90.88) price target on Reckitt Benckiser and gave the stock a neutral rating in a report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Reckitt Benckiser currently has a consensus rating of Hold and a consensus target price of GBX 7,045.22 ($95.57).
LON RB opened at GBX 5,756 ($78.08) on Friday. Reckitt Benckiser has a 52-week low of GBX 5,562 ($75.45) and a 52-week high of GBX 8,110.43 ($110.02).
The business also recently declared a dividend, which will be paid on Thursday, May 24th. Stockholders of record on Thursday, April 12th will be given a dividend of GBX 97.70 ($1.33) per share. This represents a dividend yield of 1.65%. This is an increase from Reckitt Benckiser’s previous dividend of $66.60. The ex-dividend date is Thursday, April 12th.
In other news, insider Rakesh Kapoor sold 120,000 shares of Reckitt Benckiser stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of GBX 5,576 ($75.64), for a total transaction of £6,691,200 ($9,076,505.70).
Reckitt Benckiser Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.